top of page
external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus. 
Explore the latest updates from the life science industry.

Popular Content.

PHARMA

EyePoint’s DURAVYU misses first Phase 3 endpoint in wet AMD, putting focus on second trial

EyePoint says an unusual imbalance in unrelated vision loss affected LUGANO results, while secondary data point to reduced treatment burden.

 Featured Articles. 

7-format11240.jpg
PHARMA

AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma

7-format11240.jpg
BIOTECH

Using Jumping Genes for Safer, More Accurate DNA Editing

7-format11240.jpg
BIOTECH

Tecan Brings Agentic AI to the Lab Bench with NVIDIA-powered Introspect Upgrade

7-format11240.jpg
PHARMA

Sanofi halts amlitelimab development for atopic dermatitis following pipeline review

7-format11240.jpg
HEALTH

A New Device Could Improve How Progesterone is Delivered in Early Pregnancy

7-format11240.jpg
BIOTECH

Moving research out of the lab is key to UK life science success

7-format11240.jpg
PHARMA

How Automation is Accelerating Drug Discovery Timelines

7-format11240.jpg
BIOPROCESSING

Bioreactors and Cell Culture Media: A Practical Comparison for Upstream Bioprocessing

7-format11240.jpg
PHARMA

AI in Science Writing and the Imitation of Understanding

 Latest News. 

18th August, 2026

01.

EyePoint’s DURAVYU misses first Phase 3 endpoint in wet AMD, putting focus on second trial

EyePoint says an unusual imbalance in unrelated vision loss affected LUGANO results, while secondary data point to reduced treatment burden.

17th August, 2026

02.

Tagomics launches cfDNA platform for multi-organ drug safety monitoring

Cambridge-based precision medicine company introduces LiquiPath to support earlier detection of treatment-related toxicity across the drug development lifecycle.

16th August, 2026

03.

SynGenSys expands synthetic promoter library to boost CHO cell productivity

Sheffield-based biotech launches CHO.SET 2.0 to improve protein titres and streamline biopharmaceutical manufacturing.

15th August, 2026

04.

Calla Lily joins $50m Wellcome Leap programme to advance targeted UTI treatment

London-based women’s health company will evaluate its Callavid drug delivery platform as part of a programme targeting antibiotic resistance.

Editor's Selects.

AI in Science Writing and the Imitation of Understanding

First Human Egg ‘Rejuvenation’ Offers Hope for Older IVF Patients

A Simple Pad Could Transform Cervical Cancer Screening

A New Device Could Improve How Progesterone is Delivered in Early Pregnancy

Stay up-to-date. Connect with BioFocus on LinkedIn or subscribe to our mailing list.

bottom of page